Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly those affecting children. The company has three approved medications: LIVMARLI® (maralixibat) for cholestatic pruritus in Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile acid synthesis disorders, and CTEXLI™ (chenodiol) for cerebrotendinous xanthomatosis. Mirum is also advancing a pipeline of investigational treatments, including Volixibat for primary sclerosing cholangitis and Fragile X syndrome, showcasing its commitment to innovative solutions in rare disease therapy.
Mirum Pharmaceuticals is seeking a patient navigator to serve as the primary liaison for patients, caregivers, and healthcare providers. The role involves providing seamless transitions from prescription to ongoing therapy, facilitating clear communication, and ensuring patient and provider experiences are elevated. This position requires a compassionate individual who can navigate complex access barriers within rare disease care.
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly those affecting children. The company has three approved medications: LIVMARLI® (maralixibat) for cholestatic pruritus in Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile acid synthesis disorders, and CTEXLI™ (chenodiol) for cerebrotendinous xanthomatosis. Mirum is also advancing a pipeline of investigational treatments, including Volixibat for primary sclerosing cholangitis and Fragile X syndrome, showcasing its commitment to innovative solutions in rare disease therapy.